Navigation Links
Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur

- Blood pressure reduction achieved at 8 am versus placebo: - 25 / - 13 mm Hg (systolic / diastolic, p<0.0001 / p=0.0035)
- Blood pressure reduction dependent on vaccine dose and induced antiangiotensin II antibody levels
- Detailed results presented today at the Seventeenth European Meeting on Hypertension in Milan, Italy

SCHLIEREN (Zurich), Switzerland and MILAN, Italy, June 17, 2007 - Cytos Biotechnology AG (SWX:CYTN) presented today new clinical data on its hypertension vaccine CYT006-AngQb at the Seventeenth European Meeting on Hypertension in Milan, Italy. The vaccine candidate was tested in a placebocontrolled, double-blind phase IIa clinical trial in 72 patients with mild to moderate hypertension.

On January 26, 2007, Cytos Biotechnology reported top-line data from this study, which showed that the 300 ?g dose of the vaccine was safe, very well tolerated and efficacious in lowering day-time ambulatory blood pressure. The new data presented today show a particularly strong efficacy of the vaccine in early morning hours, a critical time period when serious cardiovascular events frequently occur. The graph below shows the mean ambulatory blood pressure during the 24-hour measurement period 14 weeks after the first injection of the vaccine or of placebo. The early morning rise of blood pressure starting at 5 am was significantly suppressed by the vaccine, leading at 8 am to a change from baseline of the blood pressure of - 25 / - 13 mm Hg compared to placebo (SBP / DBP, p<0.0001 / p=0.0035).


*SEE ATTACHMENT FOR FIGURE*

The strong suppression of the early morning rise of blood pressure was associated with an exceptionally low increase in plasma renin concentration (PRC) from a mean renin concentration of 5.1 pg/ml at baseline to 6.3 pg/ml at week 14 (p=0.02). Inhibition of the renin-angiotensin system by small molecule drugs is known to induce a reactive rise of the plasma renin concentrati
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
7. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
8. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
9. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
10. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:9/19/2014)... Larry J. Merlo , President and CEO of CVS ... National Press Club in Washington, D.C. ... selling tobacco products and its leadership in driving the innovations ... changes in our health care system pose enormous challenges to ... "CVS Health has a truly unique combination of business assets ...
(Date:9/19/2014)... Mass. , Sept. 19, 2014  Pressure ... today announced it has received and approved all ... HT48 instruments and has begun to manufacture the ... first instrument will be ready for shipment by ... built and released at a rate of about ...
(Date:9/19/2014)... ORLANDO, Fla. , Sept. 19, 2014 ... continues to grow, with the publication of two papers ... Otolaryngology – Head and Neck Surgery ... of both objective and subjective measures of sleep disordered ... therapy for the reduction in obstructive sleep apnea severity ...
Breaking Medicine Technology:CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4
... Covance Inc. (NYSE: CVD ) today announced that it will ... Wednesday, June 16, 2010 at 3:00 p.m. (ET) .  Investors may ... to register and download any necessary software, please log on 10 minutes early. ... Covance, with headquarters in Princeton, ...
... The Fifth Annual Orthopedic Design & Technology (ODT) Conference & Exhibition is set to ... Wayne, Ind. , , , ... together orthopedic finished good manufacturers, suppliers and surgeons for networking, general sessions, panel discussions, ... , , "This ...
Cached Medicine Technology:Fifth Annual Orthopedic Design & Technology Conference & Exhibition Set for September 22-23 2Fifth Annual Orthopedic Design & Technology Conference & Exhibition Set for September 22-23 3
(Date:9/20/2014)... (PRWEB) September 20, 2014 As ... http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgeries continue to ... insurer has announced plans to end coverage for ... its website last month, Harrisburg, Pennsylvania-based Capital BlueCross ... 1, 2014. The insurer said its decision was ...
(Date:9/20/2014)... PITTSBURGH, PA (PRWEB) September 20, 2014 "As ... left in their tanks," said an inventor from Tamaqua, Pa. ... are mounted on the backs of their chairs. My invention ... She developed the Kam Oxygen Sensor to make it easier ... ensures that the user knows when the tank is low. ...
(Date:9/20/2014)... September 20, 2014 RBSEO Services, which ... marketing companies, has announced it provides an affordable website ... , This announcement would benefit those new and ... market but cannot afford to pay a big amount ... visibility of their websites in top search results for ...
(Date:9/20/2014)... MarijuanaDoctors.com recently returned to New ... PAIN Week conference that was held at the ... Las Vegas from September 2nd to September 6th. ... in the hopes of educating physicians in regards ... tool to treat chronic Pain, MarijuanaDoctors.com accomplished goals ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Are you ... because of problems with seasonal allergies or sinus congestion? ... much better alternative. , She conceived of Nose ... having a runny nose in public. Since it prevents ... promotes more sanitary conditions, particularly when cooking or working ...
Breaking Medicine News(10 mins):Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:RBSEO Services Announces Affordable Website SEO Service at Only $175 2Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:Nasal Drip Eliminator Invented by InventHelp Client (LCC-218) 2
... institutions in Sweden are among the quickest to adopt a ... ( JoVE ), with over 35 percent of institutions ... this phenomenon is that Swedes are among the fastest people ... we are a very curious people and interested in new ...
... breakfast and lunch lose less weight compared to those who ... by researchers at Fred Hutchinson Cancer Research Center., The results ... a member of the Hutchinson Center,s Public Health Sciences Division ... the December issue of the Journal of the American ...
... risk of a second primary cancer of the same type, ... Canadian Medical Association Journal ) (pre-embargo link only) http://www.cmaj.ca/site/embargo/cmaj110167.pdf ... another type was only slightly elevated. Danish researchers looked ... 705 people) from 1980 to 2007 to determine whether ...
... Men may think about sex more often than women do, but ... needs, such as eating and sleep, more frequently than women do, ... men think about sex every seven seconds, which would amount to ... the study, the median number of young men,s thought about sex ...
... If cancer survivors develop a second cancer, it,s most likely ... researchers report. About 15 percent of cancer survivors worldwide ... the new report pointed out. In the study, investigators ... from 1980 to 2007 and found that about 10 percent ...
... use of recent experiences. Scientists from Ludwig-Maximilians-Universitt (LMU) ... test subjects to estimate distances in a virtual ... to approach the mean of all previously experienced ... to accurately predict the experimental findings using a ...
Cached Medicine News:Health News:Swedish people are quick to adopt JoVE, a video journal for biomedical sciences 2Health News:Mid-morning snacking may sabotage weight-loss efforts 2Health News:Mid-morning snacking may sabotage weight-loss efforts 3Health News:Risk of second cancer in cancer survivors mainly confined to the same cancer type as the first 2Health News:Risk of second cancer in cancer survivors mainly confined to the same cancer type as the first 3Health News:Study debunks stereotype that men think about sex all day long 2Health News:Study debunks stereotype that men think about sex all day long 3Health News:Study debunks stereotype that men think about sex all day long 4Health News:Second Cancer Often Same Type as the First, Study Finds 2Health News:When errors improve performance: Model describes how experiences influence our perception 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: